DataMeds AI Stock Drops 11% After Launching GLP-1 App

DataMeds AI (MEDS) stock plummeted by 11% on Monday after announcing the launch of its new Health Lives Here mobile app, which targets users of GLP-1 receptor agonist medications.

The Tampa-based company partnered with Tollo Health to develop the app and is marketing it through a partnership with NFL Alumni Health. The app connects users with licensed physicians for telemedicine evaluations and allows patients to get assessed for GLP-1 therapies from their phone.

The launch comes with a new health care network, starting with Moose Pharmacy of Concord in North Carolina, which offers cash-pay options for branded GLP-1 medications and home delivery. The app also sells Tollo Health's Forzet, a medical food product designed to help manage muscle loss associated with weight loss treatments.

DataMeds AI plans to expand the app to Long COVID patients in the fourth quarter of 2026 and cancer patients after that, but did not provide a specific timeline. The company also aims to add digital twin capabilities and a broader provider network by 2027.